We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Oversight of Clinical Investigators’ Finances Needs Improvement, OIG Says
FDA Oversight of Clinical Investigators’ Finances Needs Improvement, OIG Says
January 21, 2009
Sponsors of clinical trials may receive greater scrutiny of their financial ties to clinical investigators following an HHS Office of Inspector General (OIG) report recommending the agency require sponsors to submit investigators’ complete financial information in pretrial applications and ensure its staff documents reviews and takes appropriate action.